Evidence map›Paper›PMID 41399117›Full record

ArticleAnnals of transplantation2025

Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: A Retrospective Registry-Based Study Using the Korean Organ Transplant Registry (KOTRY).

Sang-Hoon Kim, Shin Hwang, Bong-Wan Kim, Dong Jin Joo, Kwang-Woong Lee, Gyu-Seong Choi, Je Ho Ryu, Dong-Sik Kim, Dongho Choi, Jai Young Cho and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sang-Hoon KimDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Shin HwangDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Bong-Wan KimDepartment of Liver Transplantation and Hepatobiliary Surgery, Ajou University School of Medicine, Suwon, South Korea.
Dong Jin JooDepartment of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Kwang-Woong LeeDepartment of Surgery, Seoul National University College of Medicine, Seoul, South Korea.
Gyu-Seong ChoiDepartment of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Je Ho RyuDepartment of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Pusan, South Korea.
Dong-Sik KimDivision of HBP Surgery and Liver Transplantation, Department of Surgery, Korea University College of Medicine, Seoul, South Korea.
Dongho ChoiDepartment of Surgery, Catholic University of Daegu, Daegu, South Korea.
Jai Young ChoDepartment of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Young Kyoung YouDepartment of Surgery, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Dongho ChoiDepartment of Surgery, Hanyang University, Seoul, South Korea.
Tae-Seok KimDepartment of Surgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
PyoungJae ParkDepartment of Surgery, Korea University Guro Hospital, Korea University College of Medicine,, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare primary liver tumor with poor prognosis. This retrospective study aimed to evaluate the outcomes and prognostic factors of 40 patients who underwent liver transplantation (LT) for cHCC-CC using data from the Korean Organ Transplant Registry (KOTRY). MATERIAL AND METHODS A cohort of 40 LT recipients diagnosed with cHCC-CC was selected from the KOTRY database between 2014 and 2019. Survival analyses were performed according to key clinicopathological variables, and risk factor analyses were conducted for overall survival (OS) and recurrence-free survival (RFS). RESULTS During a median follow-up of 21.4 months, 10 patients (25.0%) died and 9 patients (22.5%) experienced tumor recurrence. The 1-, 2-, and 3-year OS rates were 91.8%, 76.2%, and 59.3%, respectively, and the corresponding RFS rates were 88.8%, 70.5%, and 50.2%. Patients with a MELD score <20 (P=0.017) and a single tumor <3 cm (P=0.046) showed significantly better OS. On multivariate analysis, MELD score ≥20 (P=0.04), perineural invasion (P=0.04), and portal vein tumor thrombosis (P=0.005) were independent risk factors for poor OS, whereas microvascular invasion (P=0.01) was an independent risk factor for poor RFS. CONCLUSIONS LT can be a feasible treatment option for patients with early-stage cHCC-CC, providing favorable long-term survival. As most prognostic factors identified were pathology-related, further studies are needed to refine the selection criteria for LT candidates in this population.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsLiver TransplantationAdultAgedFemaleHumansMaleMiddle AgedPrognosisRegistriesRepublic of KoreaRetrospective StudiesRisk Factors

Identifiers

PMID41399117
PMCPMC12764160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.